

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
04 May 2023 (04.05.2023)



(10) International Publication Number  
**WO 2023/072877 A1**

|                                           |                                            |                                 |
|-------------------------------------------|--------------------------------------------|---------------------------------|
| (51) International Patent Classification: | PCT/EP2022/079311                          |                                 |
| <i>A61K 38/20</i> (2006.01)               | <i>A61F 7/08</i> (2006.01)                 | 20 October 2022 (20.10.2022) EP |
| <i>A61K 38/21</i> (2006.01)               | <i>A61K 31/455</i> (2006.01)               | PCT/EP2022/079313               |
| <i>A61K 35/17</i> (2015.01)               | <i>A61P 29/00</i> (2006.01)                | 20 October 2022 (20.10.2022) EP |
| <i>A61P 19/02</i> (2006.01)               | <i>A61P 37/02</i> (2006.01)                | PCT/EP2022/079314               |
| <i>A61F 7/02</i> (2006.01)                | <i>A61K 38/18</i> (2006.01)                | 20 October 2022 (20.10.2022) EP |
| <i>A61K 9/06</i> (2006.01)                |                                            | PCT/EP2022/079325               |
| (21) International Application Number:    | PCT/EP2022/079665                          | 20 October 2022 (20.10.2022) EP |
| (22) International Filing Date:           | 24 October 2022 (24.10.2022)               | PCT/EP2022/079315               |
| (25) Filing Language:                     | English                                    | 20 October 2022 (20.10.2022) EP |
| (26) Publication Language:                | English                                    | PCT/EP2022/079316               |
| (30) Priority Data:                       | 21204596.7 25 October 2021 (25.10.2021) EP | 20 October 2022 (20.10.2022) EP |
|                                           |                                            | PCT/EP2022/079317               |
|                                           |                                            | 20 October 2022 (20.10.2022) EP |
|                                           |                                            | PCT/EP2022/079319               |
|                                           |                                            | 20 October 2022 (20.10.2022) EP |
|                                           |                                            | PCT/EP2022/079318               |
|                                           |                                            | 20 October 2022 (20.10.2022) EP |

(54) Title: PHARMACEUTICAL COMPOSITION AND KIT COMPRISING AN IMMUNOMODULATORY SUBSTANCE FOR TREATING DISEASES

#### Rheumatoid Arthritis [ICD10 M05.80]

Initial amount of CRP and the development of the CRP amounts over a treatment course of 53 weeks including controls, placebo, erroneous treatment and correct treatment in a patient suffering from rheumatoid arthritis

Patient 1




Fig. 10

(57) Abstract: The invention relates to an immunomodulatory substance(s) and/or a skin-conditioning agent for use in a method for treating and/or preventing an inflammatory disease, immunological disease and/or autoimmune disease in a subject, wherein the method comprises a step (A) selected from one or more of: generating an accumulation of PBMCs within the skin, generating a vasodilation of the capillaries within the skin, generating an increased blood volume within the skin, generating an increased sO<sub>2</sub> within the skin, generating an increased rHb within the skin, generating an increased temperature on the skin, generating a redness on the skin, administering conditioning energy to the skin, administering a skin-conditioning agent to the skin or administering PBMCs to the skin of the subject; and the method further comprises step (B) administering a first immunomodulatory substance(s) to the skin of the subject and/or step (C) administering a second immunomodulatory substance(s) to the skin of the subject.

[Continued on next page]

PCT/EP2022/079320  
20 October 2022 (20.10.2022) EP  
PCT/EP2022/079321  
20 October 2022 (20.10.2022) EP  
PCT/EP2022/079328  
20 October 2022 (20.10.2022) EP  
PCT/EP2022/079322  
20 October 2022 (20.10.2022) EP  
PCT/EP2022/079323  
20 October 2022 (20.10.2022) EP  
PCT/EP2022/079324  
20 October 2022 (20.10.2022) EP  
PCT/EP2022/079326  
20 October 2022 (20.10.2022) EP

(71) **Applicant:** ELLENNBE GMBH [DE/DE]; Stallauer-Berg-Weg 11, 83670 Bad Heilbrunn (DE).

(72) **Inventor:** NEUMANN, Lydia Ellen; Stallauer-Berg-Weg 11, 83670 Bad Heilbrunn (DE).

(74) **Agent:** KADOR & PARTNER PART MBB; Corneliusstr. 15, 80469 Munich (DE).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))